-
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
28 Apr 2025 10:35 GMT
… metastatic castration-resistant prostate cancer (mCRPC), as … clinicopathological and treatment profiles to men … receptor pathway inhibitors (abiraterone acetate or enzalutamide … Victoria, Australia., Medical Oncology, Peter MacCallum Cancer Centre, Melbourne …
-
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
25 Apr 2025 11:10 GMT
… Medicare to inform treatment decisions for patients across the full continuum of prostate cancer … advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone … study of the STAMPEDE AAP trial. Ann Oncol. 2022;33( …
-
Trial Compares Treatments for Oligometastatic Prostate Cancer
24 Apr 2025 14:03 GMT
… ADT) and chemotherapy, treatment options for … treatments that sensitize tumors to radiation. The inclusion of abiraterone … prostate cancer therapy evolves with precision medicine at its core, the NEAR-TOP trial … prostate cancer, participation in such trials …
-
Expert Panel Addresses 5 Areas of Need in Metastatic Prostate Cancer
23 Apr 2025 16:20 GMT
… treatment paradigms for different genotypes of prostate cancer,” he added.
Next Steps
Noncastrating treatments … trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer …
-
The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan).
23 Apr 2025 16:17 GMT
… starting treatment on clinical outcomes in men with metastatic castration-sensitive prostate cancer … , 1262 (5.6%) on abiraterone acetate plus prednisone + ADT, and … School of Medical Sciences, Kyushu University, Fukuoka, Japan., Janssen Pharmaceuticals LLC, …
-
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer - Beyond the Abstract
22 Apr 2025 23:57 GMT
… prostate cancer (mCRPC), such as taxane chemotherapy … , regular medications, and potential drug interactions, in … trials show a consistent benefit for triplet treatment with abiraterone … et al. Abiraterone for Prostate Cancer Not Previously Treated …
-
Current and future directions in theranostics for neuroendocrine prostate cancer.
22 Apr 2025 16:05 GMT
Neuroendocrine prostate cancer (NEPC) is … abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate … advancements in nuclear medicine have provided a promising … this rapidly evolving field.
Cancer treatment reviews. 2025 Apr 09 …
-
AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer
22 Apr 2025 02:24 GMT
… 3 clinical trials: the PROfound … abiraterone and prednisolone in adult patients who have not received prior chemotherapy … in the treatment of prostate cancer patients. Jeong … cancer.
Pharmaceutical industry officials have consistently pointed out that drugs …
-
Broader ARPI Arsenal Enables Personalized, Cost-Conscious Treatment Selection in Prostate Cancer
21 Apr 2025 16:07 GMT
… are currently 4 FDA-approved ARPIs for the treatment of prostate cancer: abiraterone acetate (Zytiga …
-
Manchester student’s skin cancer shock at conference after seeing similar mole on screen
25 Apr 2025 10:30 GMT
… two more years of Medicine before becoming a doctor.
Alexia Strickson is … of the Human Papillomavirus Virus vaccine, which is expected to prevent … development of abiraterone - a drug that gives men with advanced prostate cancer more …
About
© 1995-2025